Trial Profile

A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vormatrigine (Primary)
Indications Epilepsy; Seizures
Focus Registrational; Therapeutic Use
Acronyms POWER1
Sponsors Praxis Precision Medicines

Most Recent Events

28 Feb 2025 Status changed from not yet recruiting to recruiting, According to Praxis Precision Medicines media release.
16 Aug 2024 New trial record
13 Aug 2024 According to Praxis Precision Medicines media release, topline results for this trial are in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com